Profusa (PFSA) Stock: Announces Key Changes to Senior Secured Convertible Notes for Stronger Financial Health

Table of Contents

TLDR:

Profusa restructures Senior Secured Convertible Notes for flexibility and reduced dilution.

Conversion floor price rises to $0.35, eliminating cash and equity amortization payments.

New payment structure includes higher mandatory ELOC payments and adjustments for shares under Form S-1.

Restructuring aims to enhance shareholder value and support Profusa’s growth strategy.
Profusa focuses on accelerating partnerships and inventory build with financial flexibility.

Profusa ( PFSA), a digital health company known for its tissue-integrated biosensors, has restructured its Senior Secured Convertible Notes. As of December 30, 2025, the company’s stock price stands at $0.50, reflecting the market’s response to these changes. The adjustments are part of Profusa’s broader strategy to enhance financial flexibility, reduce dilution, and prepare for future growth.

Key Changes to Profusa’s Senior Secured Convertible Notes

One of the most notable changes is the increase in the conversion floor price of the notes, which has risen from $0.10 to $0.35. This increase is designed to reduce the risk of significant dilution for existing shareholders. Profusa has eliminated mandatory cash and equity amortization payments, which were scheduled to start in the first quarter of 2026. The amended terms now stipulate a final payment due at the maturity of the notes, which is 18 months from issuance.

The restructuring also includes important changes to Profusa’s mandatory ELOC payments. These payments have risen from 17.5% to 33% for shares issued under the current registration statement. Furthermore, for any shares issued under future filings on Form S-1, the required ELOC payments will increase to 50%. These changes reflect the company’s effort to strengthen its financial position and reduce overall debt.

Strengthening Profusa’s Financial Health and Strategic Growth

Profusa’s CFO, Fred Knechtel, emphasized that these changes will provide the company with increased flexibility while minimizing dilution. The restructuring is a key component of the company’s ongoing balance sheet recapitalization efforts. Knechtel also highlighted the importance of these changes in positioning Profusa for continued growth. The adjustments will allow the company to allocate more resources to its development initiatives, partnerships, and inventory building efforts.

The restructuring comes at a time when Profusa is focused on advancing its innovative biosensor technology platform. The company’s next-generation biosensors provide continuous monitoring of biochemistry, with potential applications in healthcare and chronic disease management. CEO Ben Hwang expressed confidence that these changes will accelerate the company’s path to revenue growth while creating value for shareholders.

Profusa’s decision to restructure its Senior Secured Convertible Notes marks a crucial step toward improving its financial stability. With these changes, the company is better positioned to drive its growth initiatives, including expanding partnerships and advancing its technology. The company remains optimistic that these financial adjustments will lead to long-term success and increased enterprise value.